Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review.

Abstract

The management of advanced (locally advanced or metastatic) urothelial carcinoma has been revolutionized since pembrolizumab was introduced in 2017. Several prognostic factors for advanced urothelial carcinoma treated with pembrolizumab have been reported, including conventional parameters such as performance status and visceral (especially liver) metastasis, laboratory markers such as the neutrophil-to-lymphocyte ratio, sarcopenia, histological/genomic markers such as programmed cell death ligand 1 immunohistochemistry and tumor mutational burden, variant histology, immune-related adverse events, concomitant medications in relation to the gut microbiome, primary tumor site (bladder cancer versus upper tract urothelial carcinoma) and history/combination of radiotherapy. The survival time of advanced urothelial carcinoma has been significantly prolonged (or 'doubled' from 1 to 2 years) after the advent of pembrolizumab, which will be further improved with novel agents such as avelumab and enfortumab vedotin. This review summarizes the latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the contemporary era of immune checkpoint inhibitors.

• Authors: Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, Haruki Kume
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 54 Issue 3 Pg. 254-264 (Mar 09 2024) ISSN: 1465-3621 [Electronic] England
• PMID: 38109484 (Publication Type: Review, Journal Article)
• Copyright: © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Immune Checkpoint Inhibitors

Topics

• Humans
• Carcinoma, Transitional Cell (drug therapy, pathology)
• Urinary Bladder Neoplasms (drug therapy, pathology)
• Immune Checkpoint Inhibitors (therapeutic use)
• Prognosis